Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia

Haematologica

Volumn 90, Issue 10, 2005, Pages 1437-1438

  Schaar, Cees G ^a   Vermeer, Henricus J ^b   Wijermans, Pierre W ^b   Huisman, Wim ^c   Le Cessie, Saskia ^d   Kluin Nelemans, Hanneke C ^e  

^a Integraal Kankercentrum West   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; SYNDECAN 1;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; MONOCLONAL IMMUNOGLOBULINEMIA; MONOCLONAL PROTEINEMIA; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

FOLLOW-UP STUDIES; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTEOGLYCANS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYNDECAN-1; SYNDECANS;

EID: 27144505136     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ong F, Hermans J, Noordijk EM, De Kieviet W, Seelen PJ, Wijermans FW, et al. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma. Leuk Lymphoma 1997;27:495-501.
2. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000;95:388-92.
3. Dhodapkar MV, Abe E, Theus A et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998;91:2679-88.
4. Ong F, Hermans J, Noordijk EM, Wijermans PW, Seelen PJ, de Kieviet W, et al. A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands. Br J Haematol 1997;99:914-920.
5. Durie BGM, Salmon DE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
6. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of unknown significance. N Engl J Med 2002; 346:564-9.
7. Maisnar V, Touskova M, Maly J, Krejsek J, Kmonicek M, Kopecky O, et al. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma]. Vnitr Lek 2002;48:290-7.
8. Janosi J, Sebestyen A, Mikala G, Nemeth J, Kiss Z, Valyi-Nagy I. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma. Haematologica 2004;89:370-1.